Kardeh Sina, Masjedi Fatemeh, Faezi-Marian Shima, Shamsaeefar Alireza, Torabi Jahromi Mahsa, Pakfetrat Maryam, Roozbeh Jamshid
Central Clinical School, Monash University, Melbourne, Australia.
Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Transplant Proc. 2023 Oct;55(8):1924-1926. doi: 10.1016/j.transproceed.2023.07.016. Epub 2023 Sep 16.
Organ transplantation can lead to human visceral leishmaniasis (VL) transmission in humans. This report aims to describe the possible complications related to an atypical course of VL after kidney transplantation.
A 61-year-old man who suffered end-stage renal failure received a deceased donor kidney transplant after 2 years of hemodialysis. Tacrolimus, mycophenolate mofetil, and prednisolone were used for immunosuppressive therapy, and renal function remained stable for 2.5 years. He was referred to our hospital because of fever and malaise. Physical and radiological examinations showed mild splenomegaly and cervical and inguinal lymphadenopathy. Laboratory data showed bicytopenia, elevated C-reactive protein, serum creatinine, and non-nephrotic proteinuria. Bone marrow biopsy aspiration showed no abnormality. Polymerase chain reaction confirmed the diagnosis of Leishmania infantum. Anti-leishmanial therapy was initiated with liposomal amphotericin B for 2 weeks, and the patient became clinically stable. So far, there has been no evidence of clinical or biological relapse, and kidney function is stable.
Considering that VL has become increasingly widespread in immunocompromised patients in endemic regions, especially in patients with transplants, it is crucial to screen and rule out VL as a cause of infection in these patients. The probability of this problem should be considered in every patient with a transplant in endemic and nonendemic areas. Furthermore, our study showed that through timely diagnosis using noninvasive methods and standard treatments, mortality caused by this disease can be properly prevented.
器官移植可导致人类内脏利什曼病(VL)在人与人之间传播。本报告旨在描述肾移植后非典型VL病程相关的可能并发症。
一名61岁患有终末期肾衰竭的男性,在接受两年血液透析后接受了已故供体肾移植。使用他克莫司、霉酚酸酯和泼尼松龙进行免疫抑制治疗,肾功能在2.5年内保持稳定。他因发热和不适被转诊至我院。体格检查和影像学检查显示轻度脾肿大以及颈部和腹股沟淋巴结病。实验室数据显示双血细胞减少、C反应蛋白、血清肌酐升高以及非肾病性蛋白尿。骨髓活检穿刺未发现异常。聚合酶链反应确诊为婴儿利什曼原虫感染。开始使用脂质体两性霉素B进行抗利什曼原虫治疗2周,患者临床症状稳定。迄今为止,尚无临床或生物学复发的证据,肾功能稳定。
鉴于VL在流行地区的免疫功能低下患者中日益普遍,尤其是在移植患者中,对这些患者进行筛查并排除VL作为感染原因至关重要。在流行和非流行地区的每一位移植患者中都应考虑到这个问题的可能性。此外,我们的研究表明,通过使用非侵入性方法及时诊断并进行标准治疗,可以适当预防该疾病导致的死亡。